Quanterix Corporation (QTRX) filed Post-Effective Amendment No. 3 on Form S-8 to its previously declared-effective Form S-4, completing the technical step needed to register shares that will be issued under equity awards assumed from Akoya Biosciences following the recently closed merger.
- Shares registered: 253,181 shares of Quanterix common stock, representing the maximum issuable upon vesting of outstanding Akoya restricted stock units ("Rollover RSUs").
- Merger exchange ratio: each Akoya share converted at closing into 0.1470 Quanterix share plus $0.37 cash.
- Total shares previously registered: 8,357,169 on the original Form S-4, covering stock consideration to Akoya shareholders and all equity awards; today’s filing carves out only the RSU component.
- Fees: all SEC filing fees were paid with the original Form S-4; no additional fees are due.
- Plan coverage: the amendment relates to the Akoya Biosciences 2015 & 2021 Equity Incentive Plans, now assumed by Quanterix.
- Rule 416(a) applicability: automatic coverage for share increases from stock splits, dividends, or similar corporate actions.
Part II of the filing reiterates standard incorporation by reference of recent Quanterix periodic reports, describes Delaware law-based indemnification provisions, and lists exhibits, including opinions from Covington & Burling LLP and auditor consents. The document is strictly administrative—no new financial results, guidance, or strategic changes are disclosed; its primary purpose is to ensure that shares underlying assumed Akoya equity awards are properly registered for issuance post-merger.